NCT05076500 (TIMM-RAD) is a clinical trial of Biopsy and blood sample collection in Cancer, sponsored by University of Manchester.

Who is sponsoring NCT05076500?

NCT05076500 is sponsored by University of Manchester.

What drugs are being tested in NCT05076500?

Interventions in NCT05076500: Biopsy and blood sample collection.

Is NCT05076500 still recruiting?

NCT05076500 is currently recruiting now. Last updated 11 June 2025.

Last reviewed 2025-06-11 · How we verify

NCT05076500: TIMM-RAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating the Tumour Immune Response of Radiotherapy

Recruiting now Last updated 11 June 2025

What this trial tests

trial testing Biopsy and blood sample collection in Cancer in 120 participants. Currently enrolling.

Timeline

14 July 2021

Primary endpoint
14 July 2026

14 August 2026

Quick facts

Lead sponsor	University of Manchester
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	120
Start date	14 July 2021
Primary completion	14 July 2026
Estimated completion	14 August 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

Biopsy and blood sample collection

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

University of Manchester

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate immune changes which occur before and following standard radiotherapy in a range of tumour types. We will collect tissue and blood samples before and after radiation treatment from participants across six cancer types: cervical, rectal, Head and Neck cancer, nodal non-Hodgkin lymphoma, cutaneous lymphoma and cutaneous squamous cell carcinoma/ basal cell carcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Innate Immune System in the Context of Radiation Therapy for Cancer.
Boopathi E, Den RB, Thangavel C. · · 2023 · cited 14× · PMID 37568788 · DOI 10.3390/cancers15153972
Investigating the Immune Effects of Radiotherapy in Non-Small Cell Lung Cancer-Results of the PD-RAD Study.
Cheng S, Kordbacheh T, Banyard A, Chaturvedi A, et al · · 2026 · PMID 41799515 · DOI 10.32604/or.2025.072053

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University of Manchester trials

Trials by the same sponsor.

NCT07506096 — Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns · NA · not yet recruiting
NCT07084090 — Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care · NA · not yet recruiting
NCT07494760 — A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experien · NA · not yet recruiting
NCT07372885 — GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia · Phase 1, PHASE2 · not yet recruiting
NCT07381894 — Multicentre Hypertrophic Cardiomyopathy Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05076500 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manchester
Last refreshed: 11 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05076500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing